Unnamed big pharma evaluates Merrion's oral delivery platform for three compounds
This article was originally published in Scrip
Executive Summary
Merrion Pharmaceuticals, a publicly listed Irish drug development company, has announced that it has signed an oral drug delivery feasibility and option agreement with an unnamed top ten pharmaceutical company. Under the terms of the agreement, the partners will evaluate Merrion’s GIPET technology for boosting the bioavailablity of three compounds belonging to the pharma firm.